A 2-poly-substituted aromatic ring-pyrimidine type derivative, characterized by having the structure of the general formula IV: wherein: W, X, Y and Z are identical or different, and are respectively and separately selected from N, C and O; R 1 is selected from unsubstituted or substituted quinary or senary aromatic rings or aromatic heterocycles, each of the aromatic heterocycles contains 1 to 3 heteroatoms selected from O, N and S, the substituted is mono-substituted, di-substituted or tri-substituted, and the substituent group is selected from R a groups; R a is optionally selected from H, halogen, nitro, cyano, C 1-3 alkyl, halogenated CI-3 alkyl, -C(=O)OR b, -C(=O)NHRb, -NHRb, -OR b and -NHCORb; R b is optionally selected from C 1-3 alkyl; R 2 is selected from -NHR c; R c is selected from C 1-7 alkyl; R 3 is selected from H; L 1 is selected from O, S, NH or a deletion; m=0-2; R 4 is selected from nitrogen-containing quinary to octonary heterocycles; and R 5 is selected from C 1-3 alkyl; and wherein the derivative is selected from: N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(1-methyl-5-(piperidine-4-oxyl)pyrazole-3-yl)-2,4-diaminopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(3-(piperidine-4-oxyl)isoxazole-5-yl)-2,4-diam inopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(1-methyl-2-(piperidine-4-oxyl)imidazole-4-yl)-2,4-diaminopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)isothiazole-5-yl)-2,4-dia minopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)-4,5-2 H -oxazoline-5-yl)-2,4-d iaminopyrimidine, and N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)thiazole-5-yl)-2,4-diaminopyr imidine. W, X, Y and Z are identical or different, and are respectively and separately selected from N, C and O; R 1 is selected from unsubstituted or substituted quinary or senary aromatic rings or aromatic heterocycles, each of the aromatic heterocycles contains 1 to 3 heteroatoms selected from O, N and S, the substituted is mono-substituted, di-substituted or tri-substituted, and the substituent group is selected from R a groups; R a is optionally selected from H, halogen, nitro, cyano, C 1-3 alkyl, halogenated CI-3 alkyl, -C(=O)OR b, -C(=O)NHRb, -NHRb, -OR b and -NHCORb; R b is optionally selected from C 1-3 alkyl; R 2 is selected from -NHR c; R c is selected from C 1-7 alkyl; R 3 is selected from H; L 1 is selected from O, S, NH or a deletion; m=0-2; R 4 is selected from nitrogen-containing quinary to octonary heterocycles; and R 5 is selected from C 1-3 alkyl; and wherein the derivative is selected from: N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(1-methyl-5-(piperidine-4-oxyl)pyrazole-3-yl)-2,4-diaminopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(3-(piperidine-4-oxyl)isoxazole-5-yl)-2,4-diam inopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(1-methyl-2-(piperidine-4-oxyl)imidazole-4-yl)-2,4-diaminopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)isothiazole-5-yl)-2,4-dia minopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)-4,5-2 H -oxazoline-5-yl)-2,4-d iaminopyrimidine, and N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)thiazole-5-yl)-2,4-diaminopyr imidine. N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(1-methyl-5-(piperidine-4-oxyl)pyrazole-3-yl)-2,4-diaminopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(3-(piperidine-4-oxyl)isoxazole-5-yl)-2,4-diam inopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(1-methyl-2-(piperidine-4-oxyl)imidazole-4-yl)-2,4-diaminopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)isothiazole-5-yl)-2,4-dia minopyrimidine, N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)-4,5-2 H -oxazoline-5-yl)-2,4-d iaminopyrimidine, and N 4 -methyl-5-(1-methyl-1 H -pyrazole-4-yl)- N 2 -(2-(piperidine-4-oxyl)thiazole-5-yl)-2,4-diaminopyr imidine.